Home » Stocks » SBPH

Spring Bank Pharmaceuticals, Inc. (SBPH)

Nov 23, 2020 - Stock symbol was changed to FSTX
Stock Price: $1.21 USD 0.00 (0.00%)
Updated Nov 20, 2021 4:00 PM EST
Market Cap 5.22M
Revenue (ttm) n/a
Net Income (ttm) -27.52M
Shares Out 17.25M
EPS (ttm) -1.64
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Nov 20, 2021
Last Price $1.21
Previous Close $1.21
Change ($) 0.00
Change (%) 0.00%
Day's Open 1.21
Day's Range 1.15 - 1.31
Day's Volume 86,761
52-Week Range 0.80 - 4.80

News

Hide News
PRNewsWire - 2 months ago

CAMBRIDGE, England and CAMBRIDGE, Mass., Nov. 20, 2020 /PRNewswire/ -- F-star Therapeutics, Inc., (Nasdaq: FSTX, as of November 23, 2020) a clinical-stage immuno-oncology company determined to...

Other stocks mentioned: FSTX
PRNewsWire - 2 months ago

HOPKINTON, Mass., Nov. 20, 2020 /PRNewswire/ -- Please replace the release dated November 19, 2020 with the following corrected version due to revisions to the headline. The corrected release ...

GlobeNewsWire - 2 months ago

1-for-4 Reverse Stock Split to be Effective November 20, 2020 1-for-4 Reverse Stock Split to be Effective November 20, 2020

GlobeNewsWire - 2 months ago

HOPKINTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biopharmaceutical company developing novel therapeutics f...

GlobeNewsWire - 2 months ago

HOPKINTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology and ...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Spring Bank Pharmaceuticals, Inc. (NASDAQ: SB...

PRNewsWire - 4 months ago

NEW YORK, Sept. 22, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals,...

PRNewsWire - 4 months ago

NEW YORK, Sept. 3, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: Spring Bank Pharmaceuticals, Inc.

GlobeNewsWire - 5 months ago

Announced agreement for strategic combination with F-star Therapeutics to advance a pipeline of multiple clinical-stage immuno-oncology programs

PRNewsWire - 5 months ago

NEW ORLEANS, Aug. 6, 2020 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

PRNewsWire - 5 months ago

NEW YORK, Aug. 5, 2020 /PRNewswire/ --Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New ...

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)-- #Acquisition--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Spri...

PRNewsWire - 5 months ago

NEW YORK, July 31, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of director...

Business Wire - 5 months ago

NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH) and its board of directors concerning the pr...

Newsfile Corp - 5 months ago

New York, New York--(Newsfile Corp. - July 30, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orders...

GlobeNewsWire - 5 months ago

HOPKINTON, Mass. and CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH) (“Spring Bank”), a clinical-stage biop...

GlobeNewsWire - 7 months ago

-    Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roc...

GlobeNewsWire - 9 months ago

HOPKINTON, Mass., April 02, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology a...

Market Watch - 11 months ago

Spring Bank Pharmaceuticals Inc. [s; sbph] said Wednesday it is scrapping the development of inarigivir soproxil, a treatment for chronic hepatitis B virus, after a patient died during a phase...

GlobeNewsWire - 11 months ago

HOPKINTON, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatme...

Zacks Investment Research - 1 year ago

The upbeat sentiments prevailing in Wall Street make investment in small caps stocks attractive for 2020, here's why.

Other stocks mentioned: CHUY, CUBI, DKL, UCTT
Zacks Investment Research - 1 year ago

Spring Bank (SBPH) declines as it stops dosing and enrolling patients in phase IIb studies on inarigivir.

Market Watch - 1 year ago

Spring Bank Pharmaceutical Inc.'s shares slid 17% in premarket trade Thursday, after the clinical-stage biopharma company said it has stopped dosing patients in a trial of a treatment for chr...

GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Dec. 26, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatme...

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for December 24th

Other stocks mentioned: DKS, EVA, JOUT
Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals.

Zacks Investment Research - 1 year ago

Top Ranked Momentum Stocks to Buy for December 11th

Other stocks mentioned: EXPR, GCO, SEAC
GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatme...

GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatme...

GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatm...

GlobeNewsWire - 1 year ago

HOPKINTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatm...

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Spring Bank Pharmaceuticals, Inc. (SBPH).

Seeking Alpha - 1 year ago

Today, we take an in-depth look at Spring Bank Pharmaceuticals.

About SBPH

Spring Bank Pharmaceuticals, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of a range of cancers and inflammatory diseases using its proprietary small molecule nucleotide platform. The company is developing SB 11285, a next-generation immunotherapeutic cyclic dinucleotide for the treatment of selected cancers; novel STING antagonist compounds for the treatment of autoimmune and inflammatory diseases; and novel platform to enable the targeted delivery of payload molecules. It has a collaboratio... [Read more...]

Industry
Biotechnology
IPO Date
May 6, 2016
CEO
Martin J. Driscoll
Employees
30
Stock Exchange
NASDAQ
Ticker Symbol
SBPH
Full Company Profile

Financial Performance

Financial Statements